share_log
Reuters ·  Apr 25 07:30
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s Ojemdatm (Tovorafenib) for Relapsed or Refractory Braf-Altered Pediatric Low-Grade Glioma (Plgg)
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment